Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockGHRP-2 + LUV TES + MGF + Ipamorelin
Third-Party TestedPurity Standards
Total
$159.99Size
Quantity
1
Bundle & Save
Molecular Profile
Molecular Profile
Peptide blend
GHRP-2
Molecular formula
C45H55N9O6
Molecular weight
817.97 g/mol
CAS number
158861-67-7
Sequence
D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
LUV TES
Molecular formula
C221H366N72O67S
Molecular weight
5135.89 g/mol
CAS number
218949-48-5
MGF
Molecular formula
C121H200N42O39
Molecular weight
2888.16 g/mol
Sequence
YQPPSTNKNTKSQRRKGSTFEEHK
Ipamorelin
Molecular formula
C38H49N9O5
Molecular weight
711.87 g/mol
CAS number
170851-70-4
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Mechanism & Target Class
Mechanism & Target Class
GHRP-2 and Ipamorelin are short synthetic peptides built largely from non-standard and D-configured residues. GHRP-2 is a hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) and Ipamorelin is a C-terminally amidated pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2); both carry a class of small peptides that engage a G-protein-coupled receptor, and their D-amino-acid content and C-terminal amidation confer protease resistance. LUV TES is a large synthetic peptide whose sequence is based on a 44-residue hypothalamic peptide; a hexenoyl modification at the N-terminus distinguishes it structurally from the native sequence and stabilizes the molecule. MGF is a 24-residue C-terminal E-peptide fragment whose sequence (YQPPSTNKNTKSQRRKGSTFEEHK) corresponds to a mechanical-stress-induced splice variant of the IGF-1 gene (IGF-1Ec); its primary structure is distinct from that of full-length IGF-1.
Storage & Handling
Storage & Handling
Lyophilized
GHRP-2, MGF, Ipamorelin: -20°C to -80°C. LUV TES: 2–8°C.
Avoid repeated freeze-thaw cycles for GHRP-2, MGF, and Ipamorelin. Protect LUV TES from light.
References
References
Reviews
- 1
Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. (2020). JCSM Rapid Communications
- 2
Sinha DK, Balasubramanian A, Rivera-Vega MR, et al. (2020). Translational Andrology and Urology
Reviews
- 3
Mosińska P, Zatorski H, Storr M. (2017). Journal of Neuroendocrinology
- 4
Goldspink G. (2010). Endocrinology
Primary research
- 5
Beck IT, Sweeny WB, McCarter MD, et al. (2014). International Journal of Colorectal Disease
- 6
Mamputu JC, Falutz J, Potvin D, et al. (2012). Clinical Infectious Diseases
- 7
Falutz J, Mamputu JC, Potvin D, et al. (2010). Journal of Clinical Endocrinology & Metabolism
- 8
Falutz J, Allas S, Blot K, et al. (2007). New England Journal of Medicine
- 9
Pihoker C, Pescovitz OH, Rogol AD, et al. (1995). Journal of Clinical Endocrinology & Metabolism
- 10
Tauber M, Pihoker C, Rogol AD, et al. (1993). Journal of Clinical Endocrinology & Metabolism
- 11
Zhang B, Liu Z, Li X, et al. (2023). International Journal of Molecular Medicine
- 12
Venkova K, Mann W, Nelson R, et al. (2009). Journal of Pharmacology and Experimental Therapeutics
- 13
Dluzniewska J, Sarnowska A, Lee J, et al. (2005). FASEB Journal
- 14
Laferrère B, Bressler P, David D, et al. (2002). Journal of Clinical Endocrinology & Metabolism
- 15
Yang SY, Goldspink G. (2002). FEBS Letters
- 16
Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). Lancet HIV
- 17
Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. (2011). Mechanisms of Ageing and Development
- 18
Raun K, Hansen BS, Johansen NL, et al. (1998). European Journal of Endocrinology
Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
